Heidi Wang represents private and public companies in a wide range of corporate and securities matters, including private financings, mergers and acquisitions, public offerings, SEC reporting and compliance and corporate governance.
Capstan Therapeutics Announces up to $2.1 Billion Acquisition by AbbVie
June 30, 2025
Cooley advised Capstan Therapeutics, a clinical-stage biotechnology company with a mission to multiply therapeutic possibilities for patients through targeted in vivo RNA technologies, on its definitive agreement to be acquired by AbbVie.
Beta Bionics Announces Upsized $234.6 Million IPO, Concurrent $17 Million Private Placement
January 31, 2025
Cooley represented Beta Bionics, a pioneering leader in the development of advanced diabetes management solutions, in its $234.6 million initial public offering and concurrent $17 million private placement.
Wugen Closes Oversubscribed $172 Million Series B Financing
December 12, 2022
Cooley represented Wugen, a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies, on its oversubscribed $172 million Series B financing led by Abingworth and Tybourne Capital Management. Partner Tom Coll led the Cooley team.
Bright Peak Therapeutics Closes $107 Million Series B Financing
December 12, 2022
Cooley represented Bright Peak Therapeutics, a biotechnology company developing next-generation immunotherapies to treat cancer and autoimmune disease, in its $107 million Series B financing led by RA Capital. Partner Tom Coll led the Cooley team.
Poseida Therapeutics – $80.5 Million Follow-on Offering
September 7, 2022
Cooley advised the issuer for Poseida Therapeutics’ $80.5 million follow-on offering of 23,000,000 shares of common stock at a public offering price of $3.50 per share. Poseida is a clinical-stage biopharmaceutical company dedicated to utilizing its proprietary genetic engineering platform technologies to create next-generation cell and gene therapeutics. Partners Tom Coll and Charlie Kim led the Cooley team.